Head-to-head evidence
RTN-001 vs Tadalafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: PDE5 · full Hypertension pipeline
RTN-001
Developed by Retension Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07142356 (registry estimate)
Tadalafil · Adcirca
Marketed by Eli Lilly
NCT00549302 · Phase 3 · completed
This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy.
Next expected readout: January 2027 · NCT05179876 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: RTN-001's landscape · Tadalafil's landscape